초록 ▼

The present invention provides isolated peptides or the fragments derived from SEQ ID NO: 42, which bind to an HLA antigen and induce cytotoxic T lymphocytes (CTL). The peptides may include one of the above mentioned amino acid sequences with substitution, deletion, or addition of one, two, or sever

The present invention provides isolated peptides or the fragments derived from SEQ ID NO: 42, which bind to an HLA antigen and induce cytotoxic T lymphocytes (CTL). The peptides may include one of the above mentioned amino acid sequences with substitution, deletion, or addition of one, two, or several amino acids sequences. The present invention also provides pharmaceutical compositions including these peptides. The peptides of this invention can be used for treating cancer.

대표청구항 ▼

1. A method for inducing an antigen-presenting cell (APC) with CTL inducibility, wherein the method comprises a step selected from the group consisting of: (a) collecting APCs from a subject, and(b) contacting an APC with a peptide in vitro, ex vivo or in vivowherein the peptide is selected from the

1. A method for inducing an antigen-presenting cell (APC) with CTL inducibility, wherein the method comprises a step selected from the group consisting of: (a) collecting APCs from a subject, and(b) contacting an APC with a peptide in vitro, ex vivo or in vivowherein the peptide is selected from the group consisting of:an isolated peptide of less than 15 amino acids comprising an amino acid sequence as shown in SEQ ID NO: 5, andan isolated peptide of less than 15 amino acids comprising an amino acid sequence in which one or two amino acid(s) are substituted, deleted, inserted or added to an amino acid sequence as shown in SEQ ID NO: 5 to yield a modified peptide that retains the ability to bind to an HLA antigen and cytotoxic T lymphocyte (CTL) inducibility. 2. A method for inducing a CTL, comprising a step selected from the group consisting of: (a) co-culturing a CD8-positive T cell with an APC that presents on its surface a complex of an HLA antigen and a peptide, and(b) co-culturing a CD8-positive T cell with an exosome that presents on its surface a complex of an HLA antigen and the peptidewherein the peptide is selected from the group consisting of:an isolated peptide of less than 15 amino acids comprising an amino acid sequence as shown in SEQ ID NO: 5, andan isolated peptide of less than 15 amino acids comprising an amino acid sequence in which one or two amino acid(s) are substituted, deleted, inserted or added to an amino acid sequence as shown in SEQ ID NO: 5 to yield a modified peptide that retains the ability to bind to an HLA antigen and cytotoxic T lymphocyte (CTL) inducibility. 3. A method of inducing an immune response against cancer in a subject, wherein the method comprises a step of administering to the subject a peptide, or an immunologically active fragment thereof, wherein the peptide is selected from the group consisting of: an isolated peptide of less than 15 amino acids comprising an amino acid sequence as shown in SEQ ID NO: 5, andan isolated peptide of less than 15 amino acids comprising an amino acid sequence in which one or two amino acid(s) are substituted, deleted, inserted or added to an amino acid sequence as shown in SEQ ID NO: 5 to yield a modified peptide that retains the ability to bind to an HLA antigen and cytotoxic T lymphocyte (CTL) inducibility. 4. The method of claim 1, wherein the peptide consists of the amino acid sequence of SEQ ID NO: 5. 5. The method of claim 1, wherein the peptide has one or both of the following characteristics: (a) the second amino acid from the N-terminus of the amino acid sequence of SEQ ID NO: 5 is substituted with methionine; and(b) the C-terminal amino acid of the amino acid sequence of SEQ ID NO: 5 is substituted with valine or leucine. 6. The method of claim 2, wherein the peptide consists of the amino acid sequence of SEQ ID NO: 5. 7. The method of claim 2, wherein the peptide has one or both of the following characteristics: (a) the second amino acid from the N-terminus of the amino acid sequence of SEQ ID NO: 5 is substituted with methionine; and(b) the C-terminal amino acid of the amino acid sequence of SEQ ID NO: 5 is substituted with valine or leucine. 8. The method of claim 3, wherein the peptide consists of the amino acid sequence of SEQ ID NO: 5. 9. The method of claim 3, wherein the peptide has one or both of the following characteristics: (a) the second amino acid from the N-terminus of the amino acid sequence of SEQ ID NO: 5 is substituted with methionine; and(b) the C-terminal amino acid of the amino acid sequence of SEQ ID NO: 5 is substituted with valine or leucine.